Technology | Mammography | March 27, 2018

Siemens Healthineers Announces FDA Clearance of Mammomat Revelation Mammography System

3-D HD Breast Biopsy enables more targeted, accurate biopsies; automated breast density measurement allows immediate risk stratification at the point of care

Siemens Healthineers Announces FDA Clearance of Mammomat Revelation Mammography System

March 27, 2018 — The U.S. Food and Drug Administration (FDA) has cleared Siemens Healthineers’ Mammomat Revelation premium mammography platform with the new InSpect integrated specimen imaging tool and the new HD Breast Biopsy solution for one-click targeting of suspicious areas. These and other features are designed to expand precision medicine and improve the patient experience.

Mammomat Revelation’s InSpect integrated specimen imaging tool permits imaging and real-time review of biopsy samples at the workstation. This tool improves biopsy workflow, shortens compression time and reduces patient discomfort.

HD Breast Tomosynthesis offers the widest image acquisition angle available at 50 degrees, according to Siemens. The wide angle delivers what the company calls the industry’s highest depth resolution for better separation of overlapping breast tissue, providing high-quality 3-D images for improved diagnostic confidence and earlier lesion detection. This technology is the basis for Mammomat Revelation’s HD Breast Biopsy solution, which enables one-click targeting of suspicious areas with a +/- 1mm accuracy.

Nearly half of all women in the United States who receive mammograms have dense breasts,¹ complicating efforts to identify breast lesions. Typically, the radiologist assesses fibroglandular breast density visually after the patient has left the facility. Mammomat Revelation is the first platform to offer automated breast density measurement during the mammogram for immediate, personalized risk stratification and more personalized care.

Mammomat Revelation’s Personalized Soft Compression adjusts the level of breast compression automatically to suit each patient’s anatomy.  Coupled with ergonomic SoftComp Paddles, Personalized Soft Compression enables improved breast positioning, more consistent image quality, and less discomfort and anxiety.

And for inconclusive cases, the system offers titanium contrast-enhanced mammography as a cost-effective alternative to magnetic resonance imaging (MRI), reducing scheduling conflicts and reassuring the patient.

For more information: www.usa.healthcare.siemens.com

References

1. National Cancer Institute, https://www.cancer.gov/types/breast/breast-changes/dense-breasts

Related Content

Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Sponsored Content | Videos | Mammography | January 24, 2020
Imaging Technology News Contributing Editor Greg Freiherr interviewed...
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...